Regression of Left Ventricular Mass with Captopril and Metoprolol, and the Effects on Glucose and Lipid Metabolism

References

• Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105: 173–8.
   PubMed Web of Science ®Google Scholar
• Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically deter-mined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561–6.
   Google Scholar
• Devereux RB, Pickering TG, Alderman MH, Chien S, Borer JS, Laragh JH. Left ventricular hypertrophy in hypertension. Prevalence and relationship to pathophysiologic variables. Hypertension 1987; 9: 1153–60.
   Google Scholar
• Prisant LM, Carr AA. Ambulatory blood pressure monitor-ing and echocardiographic left ventricular wall thickness and mass. Am J Hypertens 1990; 3: 81–9.
   PubMed Web of Science ®Google Scholar
• Kahan T. The importance of left ventricular hypertrophy in human hypertension. J Hypertens 1998; 16 Suppl: 23–9.
   Google Scholar
• Harada K, Komuro I, Shiojima I, et al. Pressure overload induces cardiac hypertrophy in angiotensin II type lA receptor knockout mice. Circulation 1998; 97: 1952–9.
   PubMedGoogle Scholar
• Hamawaki M, Coffman TM, Lashus A, et al. Pressure-overload hypertrophy is unabated in mice devoid of AT1A receptors. Am J Physiol 1998; 274: 868–73.
   PubMedGoogle Scholar
• Grassi G, Seravalle G, Mancia G. Left ventricular hyper-trophy and sympathetic activity. Adv Exp Med Biol 1997; 432: 173–9.
   PubMed Web of Science ®Google Scholar
• Hill DJ, Milner RD. Insulin as a growth factor. Pediatr Res 1985; 19: 879–86.
   PubMed Web of Science ®Google Scholar
• Lind L, Andersson PE, Andren B, Haenni A, Lithell HO. Left ventricular hypertrophy in hypertension is associated with the insulin resistance metabolic syndrome. J Hypertens 1995; 13: 433–8.
   Google Scholar
• Paolisso G, Galderisi M, Tagliamonte MR, et al. Myocardial wall thickness and left ventricular geometry in hyperten-sives. Relationship with insulin. Am J Hypertens 1997; 10: 1250–6.
   PubMed Web of Science ®Google Scholar
• Sundstrom J, Lind L, Nystrom N, et al. Left ventricular concentric remodeling rather than left ventricular hyper-trophy is related to the insulin resistance syndrome in elderly men. Circulation 2000; 101: 2595–600.
   PubMed Web of Science ®Google Scholar
• Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13: 1091–5.
   Google Scholar
• Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48–54.
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Pennert K, Hans son L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95–110.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998; 13: 564–9.
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–6.
   PubMed Web of Science ®Google Scholar
• Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868–73.
   Google Scholar
• Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a rando-mised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 1989; 298: 1152–7.
   PubMed Web of Science ®Google Scholar
• Pollare T, Lithell H, Morlin C, Präntare H, Hvarfner A, Ljunghall S. Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J Hypertens 1989; 7: 551–9.
   Google Scholar
• Reneland R, Andersson PE, Haenni A, Lithell H. Metabolic effects of long-term angiotensin-converting enzyme inhibi-tion with fosinopril in patients with essential hypertension: relationship to angiotensin-converting enzyme inhibition. Eur J Clin Pharmacol. 1994; 46: 431–6.
   PubMedGoogle Scholar
• Santoro D, Natali A, Palombo C, et al. Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension. Hypertension 1992; 20: 181–91.
   PubMed Web of Science ®Google Scholar
• Haenni A, Andersson PE, Lind L, Berne C, Lithell H. Electrolyte changes and metabolic effects of lisinopril/ bendrofluazide treatment. Results from a randomized, double-blind study with parallel groups. Am J Hypertens 1994; 7: 615–22.
   Google Scholar
• Andersson PE, Lithell H. Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Rela-tionship to changes in skeletal muscle blood flow. Am J Hypertens 1996; 9: 323–33.
   Google Scholar
• DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: 214–23.
   Google Scholar
• Steele R. Influences of glucose loading and injected insulin on hepatic glucose output. Ann NY Acad Sci 1959; 82: 420–30.
   PubMed Web of Science ®Google Scholar
• Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommenda-tions regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072–83.
   PubMed Web of Science ®Google Scholar
• Troy BL PJ, Rackley CE. Measurement of left ventricular wall thickness and mass by echocardiography. Circulation 1972; 45: 602–11.
   PubMedGoogle Scholar
• Devereux RB, Alonso DR, Lutas EM, et al. Echocardio-graphic assessment of left ventricular hypertrophy: com-parison to necropsy findings. Am J Cardiol 1986; 57: 450–8.
   PubMed Web of Science ®Google Scholar
• Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardi-zation, and comparison to other methods. Hypertension 1987; 9: 19–26.
   Google Scholar
• Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 1995; 25: 879–84.
   PubMed Web of Science ®Google Scholar
• Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993; 27: 341–8.
   Google Scholar
• Mazzolai L, Nussberger J, Aubert JF, et al. Blood pressure-independent cardiac hypertrophy induced by locally acti-vated renin-angiotensin system. Hypertension 1998; 31: 1324–30.
   PubMed Web of Science ®Google Scholar
• Harrap SB. Cardiovascular disease and genetics of the renin-angiotensin system. Heart 1996; 76: 13–17.
   PubMed Web of Science ®Google Scholar
• Malmqvist K, Kahan T, Edner M, et al. Regression of left ventricular hypertrophy in human hypertension with irbe-sartan. The Swedish Irbesartan Left Ventricular Hypertro-phy Investigation vs Atenolol (SILVHIA). J Hypertens 2001; 19: 1–10.
   Google Scholar
• Thiirmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hyperten-sion. Circulation 1998; 98: 2037–42.
   Google Scholar
• Koide M, Carabello BA, Conrad CC, et al. Hypertrophic response to hemodynamic overload: role of load vs. renin-angiotensin system activation. Am J Physiol 1999; 276: 350–8.
   Google Scholar
• Weinberg EO, Lee MA, Weigner M, et al. Angiotensin AT1 receptor inhibition. Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis. Circulation 1997; 95: 1592–600.
   Google Scholar
• Homcy CJ. Signaling hypertrophy: how many switches, how many wires. Circulation 1998; 97: 1890–2.
   PubMedGoogle Scholar
• Geffner ME, Golde DW. Selective insulin action on skin, ovary, and heart in insulin-resistant states. Diabetes Care 1988; 11: 500–5.
   PubMed Web of Science ®Google Scholar
• Malmqvist K, Kahan T, Isaksson H, östergren J. Left ventricular mass is not related to insulin sensitivity in never-treated primary hypertension. J Hypertens 2001; 19: 311–17.
   Google Scholar
• Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens 1998; 16: 895–906.
   PubMed Web of Science ®Google Scholar
• Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990; 39: 167–74.
   Google Scholar
• Eriksson JVV, Jansson PA, Foley K, Lithell H. Insulin sensitivity following treatment with the alpha 1-blocker bunazosin retard and the beta 1-blocker atenolol in hyper-tensive non-insulin-dependent diabetes mellitus patients. J Hypertens 1996; 14: 1469–75.
   PubMedGoogle Scholar
• Kuperstein R, Sasson Z. Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: a randomized, double-blind, controlled study of 21 obese hypertensives. Circulation 2000; 102: 1802–6.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Sekiya M, Tsuruoka T, Funada J, Kameoka H. Effect of insulin resistance on left ventricular hypertrophy and dysfunction in essential hypertension. J Hypertens 1999; 17: 1153–60.
   Google Scholar
• Paolisso G, Gambardella A, Verza M, D'Amore A, Sgambato S, Varricchio M. ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 1992; 6: 175–9.
   Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investi-gators. N Engl J Med 2000; 342: 145–53.
   Google Scholar
• Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Blood Press 1992; 1: 113–9.
   Google Scholar